{"id":"W3165566500","doi":"10.1016/s2352-3026(21)00102-2","title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Bayer Fund; Seattle Genetics; Janssen Pharmaceuticals; Gilead Sciences; Roche; Johnson and Johnson; AbbVie; Merck; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Brentuximab vedotin; Open label; Oncology; Internal medicine; Chemotherapy; Hodgkin lymphoma; Phases of clinical research; Lymphoma; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004027229,0.0002156483,0.001425761,0.00004675907,0.00007817923,0.00005087268,0.0004220437,0.0001151954,0.0005008182],"category_scores_gemma":[0.0001495727,0.0001180306,0.00008769734,0.0001352748,0.0001774732,0.0001058003,0.0001000282,0.00007340012,0.00001345231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009371566,"about_ca_system_score_gemma":0.0006408136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000328657,"about_ca_topic_score_gemma":0.00007657053,"domain_scores_codex":[0.9984325,0.0001820022,0.0004519928,0.0003976641,0.0002168085,0.0003190571],"domain_scores_gemma":[0.998346,0.0004474853,0.000267734,0.0006676709,0.0001699277,0.0001012147],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9433162,0.01188556,0.0006406595,0.0001175873,0.001205062,0.001038655,0.0004240872,0.00000128022,0.0007593516,0.01276047,0.005706649,0.02214448],"study_design_scores_gemma":[0.9313973,0.003425915,0.0002371593,0.00009633203,0.0003092886,0.0008200096,0.0001677532,0.0004474068,0.02694856,0.0002269438,0.03576969,0.0001536447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800318,0.0001488789,0.0003124553,0.01589518,0.0003163311,0.002123497,0.0001528462,0.00004060031,0.0009783343],"genre_scores_gemma":[0.9860933,0.0004831722,0.007608572,0.00293344,0.0004716432,0.0007945247,0.0004086853,0.00005030818,0.001156372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03006305,"threshold_uncertainty_score":0.5483608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07474879554476967,"score_gpt":0.3914699568134968,"score_spread":0.3167211612687272,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}